Issue 22 of Multiple Myeloma Research Review. Highlights include: • Benefits of low dose lenalidomide in relapsed/refractory MM. • Network meta-analysis: treatment outcomes in relapsed/refractory MM. • Improved outcomes for patients treated a speciality MM clinics. • Real world benefits of bortezomib regimens for non-transplant eligible MM. Download hereContinue Reading
PHYSICAL ADDRESS
Floor 7, 90 The Terrace
Wellington Central
New Zealand